Intrarenal Venous Flow Pattern Changes Do Relate With Renal Function Alterations in Acute Heart Failure.

acute heart failure intrarenal venous flow renal congestion renal function trajectory

Journal

JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241

Informations de publication

Date de publication:
22 Aug 2023
Historique:
received: 06 02 2023
revised: 12 07 2023
accepted: 19 07 2023
medline: 7 9 2023
pubmed: 7 9 2023
entrez: 7 9 2023
Statut: aheadofprint

Résumé

There is scarce evidence supporting the clinical utility of congestive intrarenal venous flow (IRVF) patterns in patients with acute heart failure. This study aims to: 1) investigate the association between IRVF patterns and the odds of worsening renal function (WRF); 2) track the longitudinal changes of serum creatinine (sCr) across IRVF at predetermined points and its association with decongestion; and 3) explore the relationship between IRVF/WRF categories and patient outcomes. IRVF was assessed at baseline (pre-decongestive therapy), 72 hours, and 30 and 90 days postdischarge. Changes in sCr trajectories across dynamic IRVF variations and parameters of decongestion were assessed using linear mixed effect models. The association between IRVF/WRF categories and outcomes was evaluated using univariable/multivariable models. In this prospective, multicenter study with 188 participants, discontinuous IRVF patterns indicated higher odds of WRF (OR: 3.90 [95% CI: 1.24-12.20]; P = 0.020 at 72 hours; and OR: 5.76 [95% CI: 1.67-19.86]; P = 0.006 at 30 days) and an increase in sCr (Δ-72 hours 0.14 mg/dL [95% CI: 0.06-0.22]; P = 0.001; Δ-discharge 0.13 mg/dL [95% CI: 0.03-0.23]; P = 0.007). However, the diuretic response and decongestion significantly influenced the magnitude of these changes. Patients exhibiting both WRF and discontinuous IRVF at 30 days experienced an increased hazard of adverse events (HR: 5.96 [95% CI: 2.63-13.52]; P < 0.001). Discontinuous IRVF identifies patients with higher odds of WRF during admission and postdischarge periods. Nonetheless, adequate diuretic response and decongestion could modify this association. Patients showing both WRF and discontinuous IRVF at 30 days had increased rates of adverse events.

Sections du résumé

BACKGROUND BACKGROUND
There is scarce evidence supporting the clinical utility of congestive intrarenal venous flow (IRVF) patterns in patients with acute heart failure.
OBJECTIVES OBJECTIVE
This study aims to: 1) investigate the association between IRVF patterns and the odds of worsening renal function (WRF); 2) track the longitudinal changes of serum creatinine (sCr) across IRVF at predetermined points and its association with decongestion; and 3) explore the relationship between IRVF/WRF categories and patient outcomes.
METHODS METHODS
IRVF was assessed at baseline (pre-decongestive therapy), 72 hours, and 30 and 90 days postdischarge. Changes in sCr trajectories across dynamic IRVF variations and parameters of decongestion were assessed using linear mixed effect models. The association between IRVF/WRF categories and outcomes was evaluated using univariable/multivariable models.
RESULTS RESULTS
In this prospective, multicenter study with 188 participants, discontinuous IRVF patterns indicated higher odds of WRF (OR: 3.90 [95% CI: 1.24-12.20]; P = 0.020 at 72 hours; and OR: 5.76 [95% CI: 1.67-19.86]; P = 0.006 at 30 days) and an increase in sCr (Δ-72 hours 0.14 mg/dL [95% CI: 0.06-0.22]; P = 0.001; Δ-discharge 0.13 mg/dL [95% CI: 0.03-0.23]; P = 0.007). However, the diuretic response and decongestion significantly influenced the magnitude of these changes. Patients exhibiting both WRF and discontinuous IRVF at 30 days experienced an increased hazard of adverse events (HR: 5.96 [95% CI: 2.63-13.52]; P < 0.001).
CONCLUSIONS CONCLUSIONS
Discontinuous IRVF identifies patients with higher odds of WRF during admission and postdischarge periods. Nonetheless, adequate diuretic response and decongestion could modify this association. Patients showing both WRF and discontinuous IRVF at 30 days had increased rates of adverse events.

Identifiants

pubmed: 37676214
pii: S2213-1779(23)00411-0
doi: 10.1016/j.jchf.2023.07.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures This work was supported by grants from the Ministry of Economy and Competitiveness, Instituto Carlos III (PI20/00392), CIBER Cardiovascular (16/11/00420 and 16/11/00403), and Heart Failure Association of the Spanish Society of Cardiology (2019). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Rafael de la Espriella (R)

Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.

Gonzalo Núñez-Marín (G)

Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.

Marta Cobo (M)

Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda (IDIPHISA), Madrid, Spain.

Daniel de Castro Campos (D)

Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda (IDIPHISA), Madrid, Spain.

Pau Llácer (P)

Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Luis Manzano (L)

Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Isabel Zegrí (I)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Álvaro Rodriguez-Pérez (Á)

Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Enrique Santas (E)

Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.

Miguel Lorenzo (M)

Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.

Gema Miñana (G)

Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.

Eduardo Núñez (E)

Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain.

Jose Luis Górriz (JL)

Department of Nephrology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain; Department of Medicine, Universitat de València. Valencia, Spain.

Antoni Bayés-Genís (A)

Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Marat Fudim (M)

Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA.

Wilfried Mullens (W)

Ziekenhuis Oost-Limburg, Genk and Hasselt University, Hasselt, Belgium.

Julio Núñez (J)

Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), Valencia, Spain; Department of Medicine, Universitat de València. Valencia, Spain; Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain. Electronic address: yulnunez@gmail.com.

Classifications MeSH